Application of quantitative pharmacology in development of therapeutic monoclonal antibodies

AAPS Journal

Volumn 12, Issue 4, 2010, Pages 592-601

  Tabrizi, Mohammad ^a   Funelas, Cherryl ^b   Suria, Hamza ^a  

^a AnaptysBio Inc   (United States)

^b Genentech   (United States)

Author keywords

Monoclonal antibodies; Pharmacodynamics (PD); Pharmacokinetics (PK); Quantitative pharmacology; Translational strategies

Indexed keywords

BEVACIZUMAB; DENOSUMAB; EPIDERMAL GROWTH FACTOR; FC RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CNTO95; MONOCLONAL ANTIBODY HAE1; OMALIZUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PANITUMUMAB; RITUXIMAB; UNCLASSIFIED DRUG; USTEKINUMAB; VASCULOTROPIN; VOLOCIXIMAB;

ADVANCED CANCER; ANGIOSARCOMA; ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN CAPTURE IMMUNOASSAY; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG MEGADOSE; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MICHAELIS MENTEN KINETICS; MODEL; MULTIPLE DRUG DOSE; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; OSTEOPOROSIS; PHARMACODYNAMICS; PHARMACOLOGY; PSORIASIS; PSORIASIS VULGARIS; QUANTITATIVE PHARMACOLOGY; RECEPTOR OCCUPANCY; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SKIN TOXICITY; STEADY STATE; UNIVERSAL IMMUNOASSAY;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOASSAY;

EID: 78649637520     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9220-2     Document Type: Review

References (108)

1. DATAMONITOR USA. Monoclonal antibodies: update 2008. June 2008.
2. La Merie SL. Top 20 biologics. R&D Pipline News. March 2009.
3. Bornstein GG, Queva C, Tabrizi M, van Abbema A, Chavez C, Wang P, et al. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Investigational New Drugs. 2009. doi: 10.1007/s10637-009-9291-z.
4. Tabrizi M, Suria H. Application of translational biomarkers in development of antibody-based therapeutics. Drug Discov. 2009;6(1):36-40. http://wwwtouchbriefingscom/ebooks/A1j0xr/drugseries/resources/indexhtm? referrerUrl=.
5. MA Tabrizi GG Bornstein SL Klakamp A Drake R Knight L Roskos 2009 Translational strategies for development of monoclonal antibodies from discovery to the clinic Drug Discov Today 14 5-6 298 305 10.1016/j.drudis.2008.12.008 19152840 1:CAS:528:DC%2BD1MXjt1Sht7k%3D
6. GG Bornstein SL Klakamp L Andrews WJ Boyle M Tabrizi 2009 Surrogate approaches in development of monoclonal antibodies Drug Discov Today 14 23-24 1159 1165 10.1016/j.drudis.2009.09.014 19853060 1:CAS:528:DC%2BD1MXhsV2murjI
7. G Suntharalingam MR Perry S Ward SJ Brett A Castello-Cortes MD Brunner, et al. 2006 Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 N Engl J Med 355 10 1018 1028 10.1056/NEJMoa063842 16908486 1:CAS:528:DC%2BD28XpsFKmtbc%3D (Pubitemid 44343545)
8. LA Buckley K Benson K Davis-Bruno M Dempster GL Finch P Harlow, et al. 2008 Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop Int J Toxicol 27 4 303 312 10.1080/ 10915810802367016 18821393 1:STN:280:DC%2BD1cnjtFSlug%3D%3D
9. Tabrizi M, Roskos LK. Exposure-response relationships for therapeutic biologic products. In: Meibohem B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs. New York: Wiley; 2006. p. 295-327.
10. M Tabrizi GG Bornstein H Suria 2009 Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease AAPS J 12 33 43 10.1208/s12248-009-9157-5 10.1208/s12248-009-9157-5 19924542 1:CAS:528:DC%2BC3cXisVGrtrs%3D
11. MA Tabrizi LK Roskos 2007 Preclinical and clinical safety of monoclonal antibodies Drug Discov Today 12 13-14 540 547 10.1016/j.drudis.2007.05.010 17631248 1:CAS:528:DC%2BD2sXnslWlurg%3D (Pubitemid 47031663)
12. Meibohm B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development. Weinheim: Wiley; 2006.
13. WS Putnam J Li J Haggstrom C Ng S Kadkhodayan-Fischer M Cheu, et al. 2008 Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody AAPS J 10 2 425 430 10.1208/s12248-008-9045-4 18686041 1:CAS:528:DC%2BD1cXhtlOgsbnM
14. NH Holford LB Sheiner 1981 Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models Clin Pharmacokinet 6 6 429 453 10.2165/00003088-198106060-00002 7032803 1:CAS:528:DyaL38XivVWhuw%3D%3D
15. NH Holford LB Sheiner 1982 Kinetics of pharmacologic response Pharmacol Ther 16 2 143 166 10.1016/0163-7258(82)90051-1 6752972 1:CAS:528: DyaL38XltF2rurg%3D (Pubitemid 12017535)
16. WJ Jusko 1994 Receptor-mediated pharmacodynamics of corticosteroids Prog Clin Biol Res 387 261 270 7972251 1:STN:280:DyaK2M%2Fmt1Cltg%3D%3D
17. WJ Jusko HC Ko 1994 Physiologic indirect response models characterize diverse types of pharmacodynamic effects Clin Pharmacol Ther 56 4 406 419 10.1038/clpt.1994.155 7955802 1:CAS:528:DyaK2MXitFWqtb8%3D
18. G Levy 1986 Kinetics of drug action: an overview J Allergy Clin Immunol 78 4 Pt 2 754 761 10.1016/0091-6749(86)90057-6 3534056 1:CAS:528: DyaL28XmtFyitb8%3D (Pubitemid 17170592)
19. G Levy M Gibaldi 1972 Pharmacokinetics of drug action Annu Rev Pharmacol 12 85 98 10.1146/annurev.pa.12.040172.000505 4625028 1:STN:280: DyaE383hvFWmuw%3D%3D
20. DE Mager E Wyska WJ Jusko 2003 Diversity of mechanism-based pharmacodynamic models Drug Metab Dispos 31 5 510 518 10.1124/dmd.31.5.510 12695336 1:CAS:528:DC%2BD3sXjt1Ggtrg%3D (Pubitemid 36444157)
21. DE Mager WJ Jusko 2001 General pharmacokinetic model for drugs exhibiting target-mediated drug disposition J Pharmacokinet Pharmacodyn 28 6 507 532 10.1023/A:1014414520282 11999290 1:CAS:528:DC%2BD38XjsFSrtro%3D (Pubitemid 34289541)
22. DE Mager WJ Jusko 2008 Development of translational pharmacokinetic- pharmacodynamic models Clin Pharmacol Ther 83 6 909 912 10.1038/clpt.2008.52 18388873 1:CAS:528:DC%2BD1cXlvFOrtb0%3D (Pubitemid 351704927)
23. LK Roskos P Lum P Lockbaum G Schwab BB Yang 2006 Pharmacokinetic/ pharmacodynamic modeling of pegfilgrastim in healthy subjects J Clin Pharmacol 46 7 747 757 10.1177/0091270006288731 16809800 1:CAS:528:DC%2BD28XntlWgsbo%3D (Pubitemid 43882798)
24. M Danhof J de Jongh EC De Lange O Della Pasqua BA Ploeger RA Voskuyl 2007 Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis Annu Rev Pharmacol Toxicol 47 357 400 10.1146/annurev.pharmtox.47.120505.105154 17067280 1:CAS:528:DC%2BD2sXit1altL0%3D
25. MA Tabrizi-Fard HL Fung 1998 Effects of nitro-l-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic- pharmacodynamic analysis Pharm Res 15 7 1063 1068 10.1023/A:1011986312541 9688061 1:CAS:528:DyaK1cXkvVWgurw%3D (Pubitemid 28356924)
26. A Garg JP Balthasar 2007 Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice J Pharmacokinet Pharmacodyn 34 5 687 709 10.1007/s10928-007-9065-1 17636457 1:CAS:528:DC%2BD2sXhtVOitr%2FO (Pubitemid 47477039)
27. ED Lobo RJ Hansen JP Balthasar 2004 Antibody pharmacokinetics and pharmacodynamics J Pharm Sci 93 11 2645 2668 10.1002/jps.20178 15389672 1:CAS:528:DC%2BD2cXpvV2isLk%3D (Pubitemid 39506617)
28. A Marathe MC Peterson DE Mager 2008 Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients J Pharmacol Exp Ther 326 2 555 562 10.1124/jpet.108.137703 18460643 1:CAS:528: DC%2BD1cXpsVWqs7o%3D
29. G Levy 1994 Pharmacologic target-mediated drug disposition Clin Pharmacol Ther 56 3 248 252 10.1038/clpt.1994.134 7924119 1:STN:280: DyaK2M%2FgvVGqsw%3D%3D
30. N Hayashi Y Tsukamoto WM Sallas PJ Lowe 2007 A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab Br J Clin Pharmacol 63 5 548 561 10.1111/j.1365-2125.2006.02803.x 17096680 1:CAS:528:DC%2BD2sXntFOrs7w%3D (Pubitemid 46632569)
31. RL Lalonde KG Kowalski MM Hutmacher W Ewy DJ Nichols PA Milligan, et al. 2007 Model-based drug development Clin Pharmacol Ther 82 1 21 32 10.1038/sj.clpt.6100235 17522597 1:CAS:528:DC%2BD2sXotVGjurc%3D (Pubitemid 46950619)
32. MA Tabrizi CM Tseng LK Roskos 2006 Elimination mechanisms of therapeutic monoclonal antibodies Drug Discov Today 11 1-2 81 88 10.1016/S1359-6446(05) 03638-X 16478695 1:CAS:528:DC%2BD28XhsFygt70%3D (Pubitemid 43227856)
33. GP Adams LM Weiner 2005 Monoclonal antibody therapy of cancer Nat Biotechnol 23 9 1147 1157 10.1038/nbt1137 16151408 1:CAS:528: DC%2BD2MXpvVyrtr0%3D (Pubitemid 41486396)
34. PJ Carter 2006 Potent antibody therapeutics by design Nat Rev 6 5 343 357 10.1038/nri1837 1:CAS:528:DC%2BD28XjslOhu7o%3D
35. PJ Carter PD Senter 2008 Antibody-drug conjugates for cancer therapy Cancer J 14 3 154 169 10.1097/PPO.0b013e318172d704 18536555 1:CAS:528: DC%2BD1cXotlWlsLo%3D Sudbury, Mass
36. K Chapman N Pullen M Graham I Ragan 2007 Preclinical safety testing of monoclonal antibodies: the significance of species relevance Nat Rev Drug Discov 6 2 120 126 10.1038/nrd2242 17268483 1:CAS:528:DC%2BD2sXhtFGlsrg%3D (Pubitemid 46745340)
37. EK Rowinsky GH Schwartz JA Gollob JA Thompson NJ Vogelzang R Figlin, et al. 2004 Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer J Clin Oncol 22 15 3003 3015 10.1200/JCO.2004.11. 061 15210739 1:CAS:528:DC%2BD2cXpsVGkur0%3D (Pubitemid 41103711)
38. CH Chau O Rixe H McLeod WD Figg 2008 Validation of analytic methods for biomarkers used in drug development Clin Cancer Res 14 19 5967 5976 10.1158/1078-0432.CCR-07-4535 18829475
39. JW Lee D Figeys J Vasilescu 2007 Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers Adv Cancer Res 96 269 298 10.1016/S0065-230X(06) 96010-2 17161683 1:CAS:528:DC%2BD1cXhs1Ontrs%3D
40. F Baert M Noman S Vermeire G Van Assche G D'Haens A Carbonez, et al. 2003 Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 348 7 601 608 10.1056/NEJMoa020888 12584368 1:CAS:528:DC%2BD3sXhtVyqtL0%3D (Pubitemid 36204954)
41. A Cassinotti S Travis 2009 Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review Inflamm Bowel Dis 15 8 1264 1275 10.1002/ibd.20899 19235918
42. I Mahmood MD Green 2005 Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins Clin Pharmacokinet 44 4 331 347 10.2165/00003088-200544040-00001 15828849 1:CAS:528: DC%2BD2MXltlCqt7Y%3D (Pubitemid 40663681)
43. R Ponce L Abad L Amaravadi T Gelzleichter E Gore J Green, et al. 2009 Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies Regul Toxicol Pharmacol 54 2 164 182 10.1016/j.yrtph.2009.03.012 19345250 1:CAS:528:DC%2BD1MXmsFymtrg%3D
44. JR Rojas RP Taylor MR Cunningham TJ Rutkoski J Vennarini H Jang, et al. 2005 Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys J Pharmacol Exp Ther 313 2 578 585 10.1124/jpet.104.079277 15647331 1:CAS:528:DC%2BD2MXktFems7o%3D (Pubitemid 40604157)
45. SL Klakamp H Lu M Tabrizi C Funelas LK Roskos D Coleman 2007 Application of analytical detection concepts to immunogenicity testing Anal Chem 79 21 8176 8184 10.1021/ac071364d 17922557 1:CAS:528:DC%2BD2sXhtFegs7%2FM (Pubitemid 350060015)
46. M Liang SL Klakamp C Funelas H Lu B Lam C Herl, et al. 2007 Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms Assay Drug Dev Technol 5 5 655 662 10.1089/adt.2007.089 17939757 1:CAS:528:DC%2BD2sXht1KgtrvL (Pubitemid 47612203)
47. D Geng G Shankar A Schantz M Rajadhyaksha H Davis C Wagner 2005 Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies J Pharm Biomed Anal 39 3-4 364 375 10.1016/j.jpba.2005.04. 045 15963677 1:CAS:528:DC%2BD2MXpsVCntrw%3D (Pubitemid 41196039)
48. Roskos LK, Kellermann S-A, Foon KA. Human antiglobulin responses. In: Lotze MT, Thompson AW, editors. Measuring immunity: basic science and clinical practice. London: Elsevier Academic; 2005. p. 172-86.
49. JL Bussiere P Martin M Horner J Couch M Flaherty L Andrews, et al. 2009 Alternative strategies for toxicity testing of species-specific biopharmaceuticals Int J Toxicol 28 3 230 253 10.1177/1091581809337262 19546261 1:CAS:528:DC%2BD1MXos1ygurk%3D
50. Z Xu T Vu H Lee C Hu J Ling H Yan, et al. 2009 Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-{alpha} human monoclonal antibody, in patients with psoriatic arthritis J Clin Pharmacol 49 9 1056 1070 10.1177/0091270009339192 19617465 1:CAS:528:DC%2BD1MXhtFChu7vL
51. Avastin. Prescribing information. 2009. http://www.gene.com/gene/ products/information/pdf/avastin-prescribing.pdf.
52. KA Papp RG Langley M Lebwohl GG Krueger P Szapary N Yeilding, et al. 2008 Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double- blind, placebo-controlled trial (PHOENIX 2) Lancet 371 9625 1675 1684 10.1016/S0140-6736(08)60726-6 18486740 1:CAS:528:DC%2BD1cXlvFymt7s%3D (Pubitemid 351671884)
53. T Shih C Lindley 2006 Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies Clin Ther 28 11 1779 1802 10.1016/j.clinthera. 2006.11.015 17212999 1:CAS:528:DC%2BD2sXhtVClsbg%3D (Pubitemid 46038527)
54. HP Gerber N Ferrara 2005 Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res 65 3 671 680 15705858 1:CAS:528:DC%2BD2MXhtVWnsb0%3D
55. L Hendeles M Asmus S Chesrown 2004 Evaluation of cytokine modulators for asthma Paediatr Respir Rev 5 A S107 S112 10.1016/S1526-0542(04)90020-6 14980253
56. TK Hart RM Cook P Zia-Amirhosseini E Minthorn TS Sellers BE Maleeff, et al. 2001 Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys J Allergy Clin Immunol 108 2 250 257 10.1067/mai.2001.116576 11496242 1:CAS:528:DC%2BD3MXmslWqsbk%3D (Pubitemid 32735409)
57. DA Mahler S Huang M Tabrizi GM Bell 2004 Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study Chest 126 3 926 934 10.1378/chest.126.3.926 15364775 1:CAS:528:DC%2BD2cXovVyks7w%3D (Pubitemid 39258050)
58. H Milgrom RB Fick Jr JQ Su JD Reimann RK Bush ML Watrous, et al. 1999 Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group N Engl J Med 341 26 1966 1973 10.1056/NEJM199912233412603 10607813 1:CAS:528:DC%2BD3cXktVaqsg%3D%3D (Pubitemid 30010404)
59. GM Walsh 2009 Mepolizumab and eosinophil-mediated disease Curr Med Chem 16 36 4774 4778 10.2174/092986709789909639 19929788 1:CAS:528: DC%2BC3cXhsVSmsbk%3D
60. S Zarogiannis KI Gourgoulianis K Kostikas 2009 Anti-interleukin-5 therapy and severe asthma N Engl J Med 360 24 2576 10.1056/NEJMc090685 19516040 1:CAS:528:DC%2BD1MXntVKqt7o%3D author reply 7
61. S Huang L Mills B Mian C Tellez M McCarty XD Yang, et al. 2002 Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma Am J Pathol 161 1 125 134 12107097 1:CAS:528:DC%2BD38Xlsl2ksrs%3D
62. XD Yang JR Corvalan P Wang CM Roy CG Davis 1999 Fully human anti- interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states J Leukoc Biol 66 3 401 410 10496309 1:CAS:528:DyaK1MXmtFequ74%3D
63. H Zhou C Hu Y Zhu M Lu S Liao N Yeilding, et al. 2009 Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis J Clin Pharmacol 50 3 257 267 19934030
64. Y Zhu C Hu M Lu S Liao JC Marini J Yohrling, et al. 2009 Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis J Clin Pharmacol 49 2 162 175 10.1177/0091270008329556 19179295 1:CAS:528: DC%2BD1MXisFCisrs%3D
65. K Margolin MS Gordon E Holmgren J Gaudreault W Novotny G Fyfe, et al. 2001 Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data J Clin Oncol 19 3 851 856 11157039 1:CAS:528:DC%2BD3MXhtlGrt7Y%3D
66. V Hsei GG Deguzman A Nixon J Gaudreault 2002 Complexation of VEGF with bevacizumab decreases VEGF clearance in rats Pharm Res 19 11 1753 1756 10.1023/A:1020778001267 12458683 1:CAS:528:DC%2BD38XotV2gs74%3D (Pubitemid 35305529)
67. MS Gordon K Margolin M Talpaz GW Sledge Jr E Holmgren R Benjamin, et al. 2001 Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 3 843 850 11157038 1:CAS:528:DC%2BD3MXhtlGrt7k%3D
68. JA Fox TE Hotaling C Struble J Ruppel DJ Bates MB Schoenhoff 1996 Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys J Pharmacol Exp Ther 279 2 1000 1008 8930210 1:CAS:528:DyaK28XntVams7c%3D
69. Georgieva A. Regulation of bone by Wnt pathway. The American Conference on Pharmacometrics, March 9-12, Tucson, Arizona, USA, 2008. http://tucson2008. go-acop.org/pdfs/7-Georgieva-FINAL.pdf.
70. CE Griffiths BE Strober P van de Kerkhof V Ho R Fidelus-Gort N Yeilding, et al. 2010 Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis New Engl J Med 362 2 118 128 10.1056/NEJMoa0810652 20071701 1:CAS:528:DC%2BC3cXnsFGjtA%3D%3D
71. R Bruno CB Washington JF Lu G Lieberman L Banken P Klein 2005 Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer Cancer Chemother Pharmacol 56 4 361 369 10.1007/s00280-005-1026-z 15868146 1:CAS:528:DC%2BD2MXmsFKlu78%3D (Pubitemid 41095399)
72. Q Chen CD Manning H Millar FL McCabe C Ferrante C Sharp, et al. 2008 CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells Clin Exp Metastasis 25 2 139 148 10.1007/s10585-007-9132-4 18064530 1:CAS:528:DC%2BD1cXmtFyhtbk%3D
73. KA Foon XD Yang LM Weiner AS Belldegrun RA Figlin J Crawford, et al. 2004 Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody Int J Radiat Oncol Biol Phys 58 3 984 990 14967460 1:CAS:528:DC%2BD2cXhtVygsr4%3D
74. RM Giusti MH Cohen P Keegan R Pazdur 2009 FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer Oncologist 14 3 284 290 10.1634/theoncologist.2008-0254 19282350 1:CAS:528:DC%2BD1MXltFekt7o%3D
75. P McLaughlin AJ Grillo-Lopez BK Link R Levy MS Czuczman ME Williams, et al. 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 8 2825 2833 9704735 1:CAS:528:DyaK1cXlsFCgu7c%3D
76. SA Mullamitha NC Ton GJ Parker A Jackson PJ Julyan C Roberts, et al. 2007 Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors Clin Cancer Res 13 7 2128 2135 10.1158/1078-0432.CCR-06-2779 17404096 1:CAS:528:DC%2BD2sXjs12rt7k%3D (Pubitemid 46649882)
77. CM Ng R Bruno D Combs B Davies 2005 Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial J Clin Pharmacol 45 7 792 801 10.1177/0091270005277075 15951469 1:CAS:528:DC%2BD2MXmsFymtLY%3D (Pubitemid 40875331)
78. YN Sun JF Lu A Joshi P Compton P Kwon RA Bruno 2005 Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects J Clin Pharmacol 45 4 468 476 10.1177/0091270004272731 15778428 1:CAS:528: DC%2BD2MXksFyhtLc%3D (Pubitemid 40490420)
79. Y Vugmeyster K Howell A Bakshl C Flores E Canova-Davis 2003 Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix Cytom A 52 2 101 109 10.1002/cyto.a.10030 1:CAS:528:DC%2BD3sXjt1yrtL8%3D
80. Y Vugmeyster K Howell K McKeever D Combs E Canova-Davis 2003 Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys Int Immunopharmacol 3 10-11 1477 1481 10.1016/S1567-5769(03)00147-4 12946444 1:CAS:528:DC%2BD3sXms1Oktro%3D (Pubitemid 37025728)
81. CM Ng S Bai CH Takimoto MT Tang AW Tolcher 2009 Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha(5)beta (1) integrin monoclonal antibody (volociximab) in cancer patients Cancer Chem Pharmacol 65 207 217 10.1007/s00280-009-1023-8 1:CAS:528:DC%2BD1MXhsVKns7bL
82. AD Ricart AW Tolcher G Liu K Holen G Schwartz M Albertini, et al. 2008 Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study Clin Cancer Res 14 23 7924 7929 10.1158/1078-0432.CCR-08-0378 19047123 1:CAS:528:DC%2BD1cXhsVegt7%2FN
83. P Ma BB Yang YM Wang M Peterson A Narayanan L Sutjandra, et al. 2009 Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors J Clin Pharmacol 49 10 1142 1156 10.1177/0091270009344989 19723673 1:CAS:528:DC%2BD1MXhtlSktbjN
84. Vectibix® (Panitumumab) Prescribing information. 2009. http://www.vectibix.com/prescribing-information/prescribing-information.html.
85. AE Kearns S Khosla PJ Kostenuik 2008 Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease Endocr Rev 29 2 155 192 10.1210/er.2007-0014 18057140 1:CAS:528:DC%2BD1cXltlOhsr0%3D (Pubitemid 351519689)
86. JJ Body T Facon RE Coleman A Lipton F Geurs M Fan, et al. 2006 A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer Clin Cancer Res 12 4 1221 1228 10.1158/1078-0432.CCR-05-1933 16489077 1:CAS:528:DC%2BD28XhsFaltLg%3D (Pubitemid 43342512)
87. A Lipton GG Steger J Figueroa C Alvarado P Solal-Celigny JJ Body, et al. 2007 Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases J Clin Oncol 25 28 4431 4437 10.1200/JCO.2007.11.8604 17785705 1:CAS:528:DC%2BD2sXht1ertrjP (Pubitemid 350013849)
88. A Lipton GG Steger J Figueroa C Alvarado P Solal-Celigny JJ Body, et al. 2008 Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy Clin Cancer Res 14 20 6690 6696 10.1158/1078-0432.CCR-07-5234 18927312 1:CAS:528:DC%2BD1cXht1Kgur3M
89. Peterson MC, Stouch BJ, Chen D, Baughman S, Holloway DL, Bekker PJ, et al. A PK/PD model developed in cynomolgus monkeys predicts concentrations and effects of AMG 162, a fully human monoclonal antibody against RANKL, in healthy postmenopausal women. AAPS, 2004. http://www.aapspharmaceutica.com/inside/focus- groups/ModelSim/imagespdfs/04Peterson.pdf
90. MR McClung 2006 Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies Curr Osteoporos Rep 4 1 28 33 10.1007/s11914-006-0012-7 16527005 (Pubitemid 44623945)
91. MR McClung EM Lewiecki SB Cohen MA Bolognese GC Woodson AH Moffett, et al. 2006 Denosumab in postmenopausal women with low bone mineral density N Engl J Med 354 8 821 831 10.1056/NEJMoa044459 16495394 1:CAS:528:DC%2BD28Xhsl2gs7o%3D (Pubitemid 43290920)
92. Facon T, Brazier M, Faucompré J, Hennache B, Leleu X, Kargar K, et al. Evaluation of urinary markers for bone resorption (Dpd, Ctx, Ntx) in patients with monoclonal gammopathy of undetermined significance and multiple myeloma. http://www.cancereducation.com/CancerSysPagesNB/abstracts/mmrf/7/aare5. pdf
93. Peterson M, Stouch B, Chen D, Baughman S, Holloway D, Bekker P, et al. A population PK/PD model describes the rapid, and sustained suppression of urinary N-telopeptidetelopeptide following administration of AMG 162, a fully human monoclonal antibody against RANKL, to healthy postmenopausal women. AAPS, 2004. http://www.aapspharmaceutica.com/inside/focus-groups/poppk/imagespdfs/ PopPKPD-2004Final.pdf
94. JR Desjarlais GA Lazar EA Zhukovsky SY Chu 2007 Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective Drug Discov Today 12 21-22 898 910 17993407 1:CAS:528:DC%2BD2sXht1ylsrbF
95. R Jefferis 2009 Glycosylation as a strategy to improve antibody-based therapeutics Nat Rev Drug Discov 8 3 226 234 10.1038/nrd2804 19247305 1:CAS:528:DC%2BD1MXisVShtb0%3D
96. R Jefferis 2009 Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action Trends Pharmacol Sci 30 7 356 362 10.1016/j.tips.2009.04.007 19552968 1:CAS:528:DC%2BD1MXotFClsro%3D
97. R Jefferis 2009 Glycosylation of antibody therapeutics: optimisation for purpose Meth Mol Biol 483 223 238 10.1007/978-1-59745-407-0-13 1:CAS:528:DC%2BD1MXhslWhtbw%3D Clifton, NJ
98. R Niwa S Hatanaka E Shoji-Hosaka M Sakurada Y Kobayashi A Uehara, et al. 2004 Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism Clin Cancer Res 10 18 Pt 1 6248 6255 10.1158/1078-0432.CCR-04-0850 15448014 1:CAS:528: DC%2BD2cXnvVOjsLg%3D (Pubitemid 39287533)
99. R Niwa E Shoji-Hosaka M Sakurada T Shinkawa K Uchida K Nakamura, et al. 2004 Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma Cancer Res 64 6 2127 2133 10.1158/0008-5472.CAN-03- 2068 15026353 1:CAS:528:DC%2BD2cXitFCgurs%3D (Pubitemid 38339463)
100. JL Reed R Kolbeck N Molfino AA Kozhich AA Humbles JS Erjefalt, et al. 2008 MEDI-563, a humanized anti-IL-5Ra antibody with enhanced effector function, induces reversible blood eosinopenia in mild asthmatics J Allergy Clin Immunol 121 2 S47 10.1016/j.jaci.2007.12.191
101. Kenakin T. Pharmacological analysis of drug-receptor interaction. New York: Raven; 1993. p. 39-68.
102. PA Baeuerle P Kufer R Bargou 2009 BiTE: teaching antibodies to engage T-cells for cancer therapy Curr Opin Mol Ther 11 1 22 30 19169956 1:CAS:528:DC%2BC3cXnt1Kgtbw%3D
103. R Bargou E Leo G Zugmaier M Klinger M Goebeler S Knop, et al. 2008 Tumor regression in cancer patients by very low doses of a T cell-engaging antibody Science 321 5891 974 977 10.1126/science.1158545 18703743 1:CAS:528: DC%2BD1cXpslWru70%3D New York, NY
104. S Argouges S Wissing C Brandl N Prang R Lutterbuese A Kozhich, et al. 2009 Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells Leuk Res 33 3 465 473 10.1016/j.leukres.2008.08.025 18835037 1:CAS:528:DC%2BD1MXhtVCqsrs%3D
105. P Kufer R Lutterbuse PA Baeuerle 2004 A revival of bispecific antibodies Trends Biotechnol 22 5 238 244 10.1016/j.tibtech.2004.03.006 15109810 1:CAS:528:DC%2BD2cXjtl2lt7g%3D (Pubitemid 38515741)
106. Q Gong Q Ou S Ye WP Lee J Cornelius L Diehl, et al. 2005 Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy J Immunol 174 2 817 826 15634903 1:CAS:528:DC%2BD2MXotFam
107. SA Hammond R Lutterbuese S Roff P Lutterbuese B Schlereth E Bruckheimer, et al. 2007 Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct Cancer Res 67 8 3927 3935 10.1158/0008-5472.CAN-06-2760 17440108 1:CAS:528:DC%2BD2sXkt1Kiu7s%3D (Pubitemid 46762182)
108. P Hoffmann R Hofmeister K Brischwein C Brandl S Crommer R Bargou, et al. 2005 Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct Int J Cancer 115 1 98 104 10.1002/ijc.20908 15688411 1:CAS:528:DC%2BD2MXjslejur0%3D (Pubitemid 40559673)